Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06149130
Status:
RECRUITING
Last Update Posted:
2024-04-15
First Post:
2023-11-20
Brief Title:
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HRHER2 - Advanced Breast Cancer
Sponsor:
Tongji Hospital
Organization:
Tongji Hospital
Study Overview
Official Title:
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HRHER2 - Advanced Breast Cancera Single-arm Phase II Exploratory Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single-arm multicenter Phase II study of patients with advanced HRHER2- breast cancer who are untreated or have failed previous first-line endocrine therapyThe primary objective of this study was to explore the efficacy and safety of the PD-L1 inhibitor adebrelimab in combination with the CDK46 inhibitor Dalpiciclib and standard endocrine therapy in advanced HR HER2-breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None